Video

Dr. Bunn on TMB as a Biomarker in Small Cell Lung Cancer

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses tumor mutational burden as a biomarker in small cell lung cancer.

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care® in Lung Cancer, discusses tumor mutational burden (TMB) as a biomarker in small cell lung cancer (SCLC).

Patients with SCLC typically have low PD-L1 expression, so using that as a biomarker won’t be very effective. Since SCLC is a diagnosis specific to smokers, these patients usually have high TMB. There is some evidence that TMB is a good biomarker, particularly with the addition of CTLA-4 inhibitors.

Bunn mentions a study of single-agent pembrolizumab (Keytruda), which demonstrated a 30% response rate in patients. The impressive thing about the responses was the durability—patients lived up to 2 years on pembrolizumab, which is much longer than chemotherapy.

Related Videos
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School